This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "Oxelumab" – news · newspapers · books · scholar · JSTOR (January 2024) |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | OX-40 ligand |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6424H9920N1704O2014S42 |
Molar mass | 144594.46 g·mol−1 |
![]() ![]() |
Oxelumab is a human monoclonal antibody designed for the treatment of asthma.[1]
Oxelumab was developed by Genentech and co-developed by Roche.
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
![]() | This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |